LyfeBulb
- Company typePrivate
- Founded2015
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
LyfeBulb firmographics
Firmographics- Name
- LyfeBulb
- Legal name
- Lyfebulb Holdings Inc.
- Website
- https://lyfebulb.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
LyfeBulb industry classification
Industry- Product category
- Patient Engagement Services
- NAICS
- Other Individual and Family Services (624190), Social Assistance (624)
- SIC
- Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)
- akta.pro secondary industry
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
Keywords
Where LyfeBulb is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
LyfeBulb business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Innovation Challenge Sponsorships: Lyfebulb partners with pharmaceutical companies, health plans, and healthcare companies as sponsors who pay to source patient-driven innovation through organized challenge events. These partnerships provide access to patient communities and insights.
- Healthcare Industry Partnerships: Bridges gap between patient communities and healthcare industry by working with sponsors looking to solve intelligent and critical problems for their patient community. Revenue generated through partnership arrangements with pharma companies and health plans.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels10 records
LyfeBulb product offering
Product offeringCore offering
Lyfebulb is a patient engagement platform that bridges chronic disease patient communities with the healthcare industry. It operates disease-specific digital community platforms (TransplantLyfe, IBDLyfe, CancerLyfe, KidneyLyfe), runs sponsored Innovation Challenges for pharmaceutical and healthcare sponsors, and delivers patient engagement services including workshops, interviews, user testing, surveys, and insight mapping across eleven chronic disease areas.
Product overview
Lyfebulb is a patient engagement and innovation accelerator platform that connects patient communities with the healthcare industry. The company operates across eleven chronic disease areas and offers a portfolio of disease-specific digital platforms (TransplantLyfe, IBDLyfe, CancerLyfe, KidneyLyfe) alongside community programs including the Ambassador Program, Entrepreneur Circle, and Innovation Challenges. These products work together to engage patients, generate insights, and drive patient-driven innovation in healthcare.
Differentiator
Problem solved
Functional benefit
Brands
- TransplantLyfe: Digital platform for transplant patients and care partners
- IBDLyfe
- CancerLyfe
- KidneyLyfe
Products and services
- TransplantLyfe A digital platform providing resources, community connection, webinars, and support for transplant patients and care partners, including the TransplantLyfe365 mobile app.
- IBDLyfe A digital community platform dedicated to supporting patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
- CancerLyfe A digital platform supporting cancer patients through their journey, including rare cancer support via RareCancerLyfe.
- KidneyLyfe A digital community empowering patients with chronic kidney disease and dialysis through connection, education, and peer support.
- Innovation Challenges Partnered innovation competitions that connect patient entrepreneurs with healthcare industry sponsors to source and fund patient-driven solutions across various disease areas, culminating in pitch competitions judged by expert panels.
- Patient Engagements Direct collaboration with patients and care partners through workshops, interviews, user testing, surveys, and research to generate insights and build impactful solutions for healthcare industry partners.
Quantifiable outcome
- Over 11 innovation challenges conducted with pharmaceutical and healthcare sponsors
- +2 more outcomes
Companies that use LyfeBulb
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles2 records
LyfeBulb technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
LyfeBulb partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship, core and minor.
- Patient Care AmericaflagshipPatient Care America announced acquisition of Lyfebulb in March 2024, combining resources to create a premier patient-focused renal solutions provider. Lyfebulb is now a Patient Care America business according to terms and conditions documentation.
- J.P. Morgan Life Sciences Private CapitalflagshipJ.P. Morgan Life Sciences Private Capital partnered with Lyfebulb to sponsor the inaugural Life Sciences Innovation Summit at Cleveland Clinic Abu Dhabi in May 2024. The summit aimed to attract early-stage entrepreneurs in life sciences to seed growth of the emerging scientific innovation hub in Abu Dhabi. 11 emerging companies were invited to pitch to an industry-renowned judging panel with potential for J.P. Morgan Life Sciences Private Capital support.
- Blue Horizon AdvisorsflagshipBlue Horizon Advisors, the independent private investment arm of a UAE family office, established a Life Sciences vertical (BHLS) and partnered with Lyfebulb as co-sponsor of the Life Sciences Innovation Summit in Abu Dhabi. Committed to becoming a prominent force within the MENA region's life sciences sector through strategic acquisitions, joint ventures, and collaborations.
- United AlSaqer GroupcoreUnited AlSaqer Group joined as co-sponsor of the J.P. Morgan Asset Management Life Sciences Innovation Summit at Cleveland Clinic Abu Dhabi, supporting the growth of the Abu Dhabi life sciences innovation ecosystem.
- Bristol Myers SquibbflagshipBristol Myers Squibb partnered with Lyfebulb for the 2022 Global Innovation Challenge addressing unmet needs in IBD. The challenge sourced innovative ideas and scalable solutions for better disease management and care, culminating in pitch competition with $50,000 in prizes ($25,000 Innovation Award + $25,000 Impact Award).
- Veloxis PharmaceuticalsflagshipVeloxis Pharmaceuticals sponsored the 2022 Innovation Challenge: Transforming Organ Transplantation held at their headquarters in Cary, North Carolina. The challenge sought solutions for transplant patient care with $40,000 in prizes ($25,000 Innovation Award + $15,000 Impact Award). Veloxis also sponsors a transplant education series with Lyfebulb and Columbia University.
- Columbia University/NewYork-Presbyterian HospitalcoreLyfebulb partnered with Columbia University and NewYork-Presbyterian Hospital for transplant patient education series. Veloxis Pharmaceuticals sponsors this transplant education series in partnership with Lyfebulb and Columbia, with webinars available on TransplantLyfe platform.
- Chris Klug FoundationminorLyfebulb partnered with the Chris Klug Foundation, participating in their Women in Transplant initiative to support and empower women in the transplant community.
- CVS Kidney CareflagshipCVS Kidney Care partnered with Lyfebulb for the 2022 Innovation Challenge focused on accelerating innovations in kidney disease to improve health equity and outcomes. The inaugural challenge addressed health disparities among CKD and ESRD patients, awarding $25,000 to OmniLife. Partnership built upon shared commitment to advancing patient-driven innovation.
- Loyola University Chicago Parkinson School of Health Sciences and Public HealthflagshipLoyola University Chicago's Parkinson School partnered with Lyfebulb for the 2021 Innovation Challenge: Meeting Our Moment - Reimagining Innovation, Improving Health Equity, and Building Resiliency. A virtual summit addressing effects of emerging infectious diseases on population health, healthcare delivery, and health equity. $75,000 distributed among up to three winners, funded by Bob and Betty Parkinson endowment.
- Arena PharmaceuticalsflagshipArena Pharmaceuticals sponsored the 2021 Imagining Life Without Limits - An Inflammatory Bowel Disease Innovation Challenge. The virtual challenge sought solutions to better equip IBD patients with tools to manage disease and improve quality of life. $25,000 Innovation Award presented to Coral Genomics.
- CSL BehringcoreCSL Behring partnered with Lyfebulb for the 2021 Innovation Challenge: Thriving with Transplantation. Celebratory conversation events and innovation challenge to support transplant patients and care partners.
- HelsinncoreHelsinn partnered with Lyfebulb for the second annual Patient-Driven Innovation Summit in Cancer. Award presented to Patient Entrepreneur demonstrating outstanding science and potential to bring cancer and cancer supportive care solutions to market.
- Crohn's & Colitis FoundationminorCrohn's & Colitis Foundation participated in the IBD Innovation Challenge as judges and advisors, contributing expertise to evaluate patient-driven innovations for inflammatory bowel disease.
- OrexocoreOrexo partnered with Lyfebulb for the 2020 Innovation Challenge in Substance Use Disorders. Challenge recognized Patient Entrepreneurs with solutions aiding successful, long-term recovery from alcohol and opioid use disorders, with $25,000 grant for the winning finalist.
Scale indicators6 records
Recent moves6 records
Expansion highlights4 records
LyfeBulb competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
LyfeBulb social profiles
Digital presenceLyfeBulb financial estimates
Financial estimateRevenue estimate
Valuation estimate
LyfeBulb leadership team
Management profileNumber of profiles
Profiles4 records
LyfeBulb funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LyfeBulb M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LyfeBulb
What does LyfeBulb do?
Lyfebulb is a patient engagement platform that bridges chronic disease patient communities with the healthcare industry. It operates disease-specific digital community platforms (TransplantLyfe, IBDLyfe, CancerLyfe, KidneyLyfe), runs sponsored Innovation Challenges for pharmaceutical and healthcare sponsors, and delivers patient engagement services including workshops, interviews, user testing, surveys, and insight mapping across eleven chronic disease areas.
Is LyfeBulb a public or private company?
LyfeBulb is a private company. It is classified as corporate owned and is currently operating.
When was LyfeBulb founded?
LyfeBulb was founded in 2015. It employs 1 to 10 people.
Where is LyfeBulb based?
LyfeBulb is headquartered in New York, United States, in the North America region.
How does LyfeBulb make money?
Two revenue lines are on record. Innovation Challenge Sponsorships are the primary driver. The others are healthcare Industry Partnerships.
Does LyfeBulb have an API?
No public API is recorded for LyfeBulb.
What industry is LyfeBulb in?
LyfeBulb's product category is Patient Engagement Services. Its primary akta.pro industry code is HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms, with a secondary code of HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D). Its NAICS code is 624190 and its SIC code is 8000.